Patents by Inventor Ara G. Hovanessian
Ara G. Hovanessian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7507417Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.Type: GrantFiled: September 27, 2005Date of Patent: March 24, 2009Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuillé
-
Patent number: 6984721Abstract: Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2, particularly, the HIV-2 proteins gp300, p200, p90, and p80, and gp300 of SIV.Type: GrantFiled: December 19, 2000Date of Patent: January 10, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuillé
-
Publication number: 20040010125Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.Type: ApplicationFiled: April 25, 2003Publication date: January 15, 2004Applicant: INSTITUT PASTEURInventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
-
Patent number: 6608179Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.Type: GrantFiled: September 22, 1999Date of Patent: August 19, 2003Assignee: Institut PasteurInventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
-
Patent number: 6261571Abstract: The invention relates to an isolated immune complex comprising a protein and an antibody that binds with said protein, wherein the protein is selected from the group consisting of gp80 of HIV-2 and gp65 of SIV, wherein said gp80 is a glycoprotein having an apparent molecular weight of 80 kDa, as determined by SDS-PAGE, and further wherein said gp65 is a glycoprotein having an apparent molecular weight of 65 kDa as determined by SDS-PAGE. Also provided are an immunogenic composition comprising an amount of gp80 protein of human immunodeficiency virus type 2 (HIV-2) sufficient to induce an immune response and a pharmaceutically acceptible carrier, and a composition comprising at least one antigen selected from the group consisting of gp80 protein of HIV-2 and gp65SIV.Type: GrantFiled: December 27, 1994Date of Patent: July 17, 2001Assignee: Institute PasteurInventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
-
Publication number: 20010006641Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp14O, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.Type: ApplicationFiled: December 19, 2000Publication date: July 5, 2001Applicant: Institut PasteurInventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuille
-
Patent number: 6197496Abstract: Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2 are disclosed. Particularly, the HIV-2 proteins, gp300, p200, p90, and p80, and gp300 of SIV are described.Type: GrantFiled: October 27, 1994Date of Patent: March 6, 2001Assignee: Institut PasteurInventors: Luc Montagnier, Anne G. Laurent Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey Cuillé
-
Patent number: 6056963Abstract: This invention is directed to a composition comprising one or more human immunodeficiency virus type 2 (HIV-2) envelope proteins and a pharmaceutically acceptable carrier. The proteins of the claimed invention are gp300, p200 and p90/80 of HIV-2. The composition is useful for the diagnostic assay of HIV-2 and as an antigen for the production of antibodies, for example.Type: GrantFiled: June 7, 1995Date of Patent: May 2, 2000Assignee: Institut Pasteur and Centre Nationale de la Recherche Scientifique (C.N.R.S.)Inventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey Cuille
-
Patent number: 5807992Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp8O was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.Type: GrantFiled: June 6, 1995Date of Patent: September 15, 1998Assignee: Institut PasteurInventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
-
Patent number: 5756477Abstract: The invention relates to a method of treating and a therapeutical composition for the treatment of Acquired Immuno Deficiency Syndrome (AIDS) and related infections. The composition comprises from 1 to 100% of a complex of Poly(A).Poly(U), preferably associated with other anti-AIDS coagents which act on the HIV virus according to a different mechanism from that of the complex of Poly(A).Poly(U). The composition is suitably administered in 100 to 4,000 mg doses and at 3 to 5 day intervals.Type: GrantFiled: January 4, 1996Date of Patent: May 26, 1998Assignee: Societe de Conseils de Recherches Et D'Applications ScientifiquesInventors: Ara G. Hovanessian, Evelyne Deschamps De Paillette
-
Patent number: 5736525Abstract: The invention relates to a method of treating and a therapeutical composition for the treatment of Acquired Immuno Deficiency Syndrome (AIDS) and related infections. The composition comprises from 1 to 100% of a complex of Poly(A).Poly(U), preferably associated with other anti-AIDS coagents which act on the HIV virus according to a different mechanism from that of the complex of Poly(A).Poly(U). The composition is suitably administered in 100 to 4000 mg doses and at 3 to 5 day intervals.Type: GrantFiled: March 13, 1997Date of Patent: April 7, 1998Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Ara G. Hovanessian, Evelyne Deschamps de Paillette
-
Patent number: 5470702Abstract: Character of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.Type: GrantFiled: January 13, 1993Date of Patent: November 28, 1995Assignee: Institut PasteurInventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
-
Patent number: 5208321Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.Type: GrantFiled: May 25, 1989Date of Patent: May 4, 1993Assignee: Institut PasteurInventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
-
Patent number: 4210746Abstract: Compounds having properties as inhibitors of protein synthesis are disclosed, of the general formula(p).sub.m --(5'--A--2'--p).sub.n --(A).sub.xwhereinp represents the phosphate group (orthophosphate),m is 0, 2, or 3A represents adenosine,n is from 2 to 5,x is 0 or 1,said compound containing at least three adenosine residues, the figures 5' and 2' signifying the carbon atoms of the ribose ring to which the respective phosphate groups p are attached.Compounds of particular interest are ApApA and its phosphorylated derivatives ppApApA and pppApApA. The substances may be prepared by chemical synthesis or enzymatic synthesis. They may be incorporated in liposomes.Type: GrantFiled: August 10, 1978Date of Patent: July 1, 1980Assignee: National Research Development CorporationInventors: Ian M. Kerr, Ronald E. Brown, Ara G. Hovanessian